We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Masimo's Neonatal RD SET Pulse Oximetry Sensors Get FDA Nod
Read MoreHide Full Article
Masimo Corporation (MASI - Free Report) received the FDA’s nod for its RD SET sensors to be used with Masimo Measure-through Motion and Low Perfusion SET pulse oximetry. The procedure is aimed at offering improved oxygen saturation (SpO2) accuracy specifications for neonatal patients weighing less than 3kgs.
Masimo stated that SpO2 accuracy specifications of the updated version of RD SET sensors greatly improved, thus enabling care providers to monitor the oxygenation status of neonates with greater confidence.
Notably, the upgraded features were first incorporated in 2018 into RD SET sensors only for patients weighing more than 3kgs. With the recent approval, the entire prenatal patient population within the United States have been brought under the purview.
With the receipt of the FDA clearance, the company aims to strengthen its core business of Measure-through Motion and Low Perfusion pulse oximetry monitoring, commonly known as Masimo SET (Signal Extraction Technology) pulse oximetry.
Significance of the Approval
Masimo’s SET pulse oximetry has been proved to be an improvement compared with other pulse oximetry technologies currently available in the market based on various independent and objective studies. The SET pulse oximetry will thus provide clinicians with increased sensitivity and specificity to make critical patient care decisions.
Notably, RD SET sensors are designed to augment patient comfort, optimize clinician workflows and help hospitals meet green initiatives. Most importantly, these sensors along with Velaid SofTouch are most suited for use on the delicate skins of newborns and pre-term babies.
Industry Prospects
Per a report by Grand View Research, the global pulse oximeters market size was valued at $1.8 billion in 2018, and is projected to witness a CAGR of 6.3% between 2019 and 2025. Factors like the huge burden of healthcare costs and the lack of defined reimbursement policies are likely to drive the market. Other contributing factors like the increasing importance of monitoring patients in treatment regime and diagnosis along with extensive occurrence of target diseases are likely to drive the market.
Given the market potential, the FDA clearance is well-timed.
Recent Developments
In December 2019, Masimo and announced the expansion of its licensing partnership with Dräger, thus enabling Dräger to integrate additional Masimo measurement technologies. The agreement was expanded to improve the assessment of brain function, oxygenation, and ventilation status by clinicians.
In October 2019, Masimo’s Radius Capnography (a portable real-time capnography, with wireless Bluetooth connectivity) received the CE marking.
Masimo announced three additional indices (delta cHb, delta HHb and delta O2Hb) for O3 Regional Oximetry in September 2019. These will provide care providers additional visibility in changes in underlying oxyhemoglobin and deoxyhemoglobin components, which are used to estimate cerebral oxygen saturation (rSO2).
Price Performance
Shares of Masimo have gained 53.8% in the past year compared with the industry’s 28.4% growth.
Zacks Rank & Stocks to Consider
Currently, the company carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Haemonetics Corporation (HAE - Free Report) , National Vision Holdings, Inc (EYE - Free Report) and Medtronic plc (MDT - Free Report) .
National Vision’s long-term earnings growth rate is estimated at 17.8%. The company currently carries a Zacks Rank #2 (Buy).
Medtronic’s long-term earnings growth rate is estimated at 7.4%. It currently carries a Zacks Rank #2.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.
Image: Bigstock
Masimo's Neonatal RD SET Pulse Oximetry Sensors Get FDA Nod
Masimo Corporation (MASI - Free Report) received the FDA’s nod for its RD SET sensors to be used with Masimo Measure-through Motion and Low Perfusion SET pulse oximetry. The procedure is aimed at offering improved oxygen saturation (SpO2) accuracy specifications for neonatal patients weighing less than 3kgs.
Masimo stated that SpO2 accuracy specifications of the updated version of RD SET sensors greatly improved, thus enabling care providers to monitor the oxygenation status of neonates with greater confidence.
Notably, the upgraded features were first incorporated in 2018 into RD SET sensors only for patients weighing more than 3kgs. With the recent approval, the entire prenatal patient population within the United States have been brought under the purview.
With the receipt of the FDA clearance, the company aims to strengthen its core business of Measure-through Motion and Low Perfusion pulse oximetry monitoring, commonly known as Masimo SET (Signal Extraction Technology) pulse oximetry.
Significance of the Approval
Masimo’s SET pulse oximetry has been proved to be an improvement compared with other pulse oximetry technologies currently available in the market based on various independent and objective studies. The SET pulse oximetry will thus provide clinicians with increased sensitivity and specificity to make critical patient care decisions.
Notably, RD SET sensors are designed to augment patient comfort, optimize clinician workflows and help hospitals meet green initiatives. Most importantly, these sensors along with Velaid SofTouch are most suited for use on the delicate skins of newborns and pre-term babies.
Industry Prospects
Per a report by Grand View Research, the global pulse oximeters market size was valued at $1.8 billion in 2018, and is projected to witness a CAGR of 6.3% between 2019 and 2025. Factors like the huge burden of healthcare costs and the lack of defined reimbursement policies are likely to drive the market. Other contributing factors like the increasing importance of monitoring patients in treatment regime and diagnosis along with extensive occurrence of target diseases are likely to drive the market.
Given the market potential, the FDA clearance is well-timed.
Recent Developments
In December 2019, Masimo and announced the expansion of its licensing partnership with Dräger, thus enabling Dräger to integrate additional Masimo measurement technologies. The agreement was expanded to improve the assessment of brain function, oxygenation, and ventilation status by clinicians.
In October 2019, Masimo’s Radius Capnography (a portable real-time capnography, with wireless Bluetooth connectivity) received the CE marking.
Masimo announced three additional indices (delta cHb, delta HHb and delta O2Hb) for O3 Regional Oximetry in September 2019. These will provide care providers additional visibility in changes in underlying oxyhemoglobin and deoxyhemoglobin components, which are used to estimate cerebral oxygen saturation (rSO2).
Price Performance
Shares of Masimo have gained 53.8% in the past year compared with the industry’s 28.4% growth.
Zacks Rank & Stocks to Consider
Currently, the company carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Haemonetics Corporation (HAE - Free Report) , National Vision Holdings, Inc (EYE - Free Report) and Medtronic plc (MDT - Free Report) .
Haemonetics currently flaunts a Zacks Rank #1 (Strong Buy) and has a projected long-term earnings growth rate of 13.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
National Vision’s long-term earnings growth rate is estimated at 17.8%. The company currently carries a Zacks Rank #2 (Buy).
Medtronic’s long-term earnings growth rate is estimated at 7.4%. It currently carries a Zacks Rank #2.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.
See 7 handpicked stocks now >>